Nephera is developing a minimally invasive catheter to protect the kidneys and treat patients with acute heart failure or who are post-cardiac surgery.

The Technology & Product

Nephera protects the kidneys from worsening injury in the acute hospital setting. The Company’s technology enables controlled inhibition of renal sympathetic nerve activity via electrical stimulation of the urinary tract – a unique approach to neural modulation and a new therapeutic modality for protecting renal function.

Nephera’s first product is a minimally invasive, single-use catheter placed in the urinary tract. The proprietary device includes a sequence of electrodes on the catheter and is connected to an external miniature pulse generator. The product is intended to provide stimulation treatment during the first few days of the patient’s hospital stay and can be used by any physician or nurse familiar with ordinary Foley urinary catheter insertion. Nephera offers a disruptive approach to protecting the kidneys and treating acute heart failure patients and post-cardiac surgery patients. Read more about the idea behind Nephera’s catheter.  


Stage: Business Development
Founded: 2008
IP: Patents issued in the U.S., China, and Australia cover stimulation of the urinary tract to affect cardiovascular and renal function.


Evidence of Physiological Effect
Nephera has conducted two pilot clinical studies demonstrating safety and tolerability, technical implementation, and initial indications of effect – dramatically enhanced diuresis (urine output) while preserving the overall health of the kidneys (GFR).

More importantly, Nephera has conducted, in cooperation with a multinational healthcare company, an extensive animal study that confirms the following:

  1. Nephera’s stimulation inhibits renal sympathetic nerve activity.
  2. The inhibition of nerve activity has a major hemodynamic effect – vasodilatation.
  3. The therapy results in less injury to the kidneys when applying accepted clinical criteria.

The Team

Robert Bash, Nephera

Nephera CEO Robert Bash presents at Trendlines 6th Annual Showcase.

  • Robert Bash, CEO: Robert joined Nephera after serving as CEO of FlowSense (automated urine output monitoring) until its sale to Baxter Healthcare. Prior to that, Robert was VP Business Development and CFO of YMed (peripheral angioplasty) until its sale to CR Bard. Before his role as a medical device executive, Robert was a partner at the U.S.-Israeli venture capital management firm, Infinity.
  • Yotam Reisner, M.D., Ph.D., VP Clinical Affairs: Yotam has more than 10 years of experience in clinical and preclinical development. He was director of clinical applications at Enopace Biomedical and Manager of Cardiovascular Research at Itamar Medical. Yotam has published a number of articles in peer-reviewed journals. He received his M.D./Ph.D. (cardiac electrophysiology) from the Technion-Israel Institute of Technology.
  • Yair Feld, M.D. Ph.D., Founder: Yair is a practicing cardiologist at Rambam Medical Center, the largest hospital in northern Israel. A serial inventor, he founded GeneGrafts, CorAssist Cardiovascular, and ProArc Medical. Yair received his M.D./Ph.D. (physiology and biophysics) from the Technion-Israel Institute of Technology, and a B.Sc. (physics) from Tel Aviv University.

The Market

The market opportunity that Nephera addresses is among the largest and most costly clinical conditions facing healthcare today. Patients in the hospital for acute heart failure and cardiac surgery suffer high incidences of renal dysfunction, known as acute kidney injury, that results in worse outcomes and higher costs of hospitalized care.

By inhibiting renal sympathetic nerve activity, Nephera can protect renal function – renal blood flow, urine and sodium excretion, and filtration. There are currently no acceptable treatment options for deteriorating renal function.

CEO Robert Bash presents at the 6th Annual Showcase. 


Robert Bash, CEO

twitter icon

Nephera logo